Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHYSIOSOL IN PLASTIC CONTAINER vs AMOXICILLIN AND CLAVULANATE POTASSIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHYSIOSOL is a sterile, non-pyrogenic isotonic solution of electrolytes (sodium, potassium, calcium, magnesium, chloride, acetate, and gluconate) in water for injection. It serves as a source of water and electrolytes to expand extracellular fluid volume and maintain osmotic balance. The acetate and gluconate ions are metabolized to bicarbonate, providing an alkalinizing effect.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Intravenous solution for fluid and electrolyte replacement in patients with isotonic or hypotonic dehydration,Maintenance of fluid and electrolyte balance during surgery or in postoperative patients,Vehicle for administration of compatible medications
Lower respiratory tract infections,Acute bacterial sinusitis,Otitis media,Urinary tract infections,Skin and skin structure infections,Bone and joint infections,Intra-abdominal infections,Dental infections
Intravenous infusion; dose based on fluid and electrolyte requirements; typical adult dose: 500-1000 m L/h as needed to maintain hydration and electrolyte balance.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
Not applicable (physiologic solution); infused electrolytes and water distribute and are eliminated with kinetics dependent on renal function; terminal half-life reflects water turnover (~3-6 days in healthy adults).
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
The acetate and gluconate ions are metabolized in the liver and peripheral tissues, primarily via the tricarboxylic acid cycle, to bicarbonate. Electrolytes (sodium, potassium, calcium, magnesium, chloride) are not metabolized but are excreted or reabsorbed as per physiological needs.
Amoxicillin undergoes partial hepatic metabolism via hydrolysis. Clavulanate is extensively metabolized in the liver, primarily by hydrolysis and conjugation.
Renal excretion of water and electrolytes; >95% of administered volume is excreted unchanged by kidneys within 24 hours; minimal (<5%) fecal or biliary elimination.
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Negligible (<1%); electrolytes are not bound to plasma proteins.
Amoxicillin: ~20% (mainly albumin); Clavulanate: ~25% (albumin).
Approximately 0.55 L/kg (total body water); distributes into extracellular fluid (0.2 L/kg) and intracellular water (0.4 L/kg).
Amoxicillin: ~0.3-0.4 L/kg; Clavulanate: ~0.3 L/kg. Distributes into tissues, not CSF unless inflamed.
Intravenous: 100%; oral: 100% (but not relevant as product is for IV use only).
Oral: ~80-90% for amoxicillin; ~60-75% for clavulanate. Enhanced with food.
No dose adjustment required; monitor serum electrolytes and fluid balance closely in renal impairment; adjust infusion rate based on renal function to avoid fluid overload.
For Cr Cl 10-30 m L/min: 250-500 mg amoxicillin component every 12 hours. For Cr Cl <10 m L/min: 250-500 mg amoxicillin component every 24 hours. Hemodialysis: 250-500 mg every 24 hours, give additional dose during and after dialysis.
No specific dose adjustment required; monitor serum electrolytes and acid-base balance in severe hepatic impairment.
No specific dose adjustment recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh C); consider alternative therapy or reduced dosing, but no formal guidelines.
Intravenous infusion; dosing based on body weight; typical dose: 10-20 m L/kg for acute replacement, then adjust based on maintenance requirements; monitor electrolyte levels.
For children >3 months: 25-45 mg/kg/day of amoxicillin component divided every 12 hours (based on 200 mg/28.5 mg per 5 m L suspension) or 20-40 mg/kg/day divided every 8 hours (based on 125 mg/31.25 mg per 5 m L suspension). For severe infections, up to 90 mg/kg/day of amoxicillin component divided every 12 hours (using 400 mg/57 mg per 5 m L suspension).
Use with caution; start with lower end of dosing range; monitor for fluid overload, electrolyte disturbances, and renal function due to age-related changes.
Initiate at lower end of dosing range due to increased risk of renal impairment. Monitor renal function and adjust dose based on creatinine clearance as per renal adjustment guidelines.
Not for injection into the epidural, intrathecal, or intra-arterial spaces. Do not administer if solution contains visible particulate matter or is discolored. Use only if solution is clear and container is undamaged.
No FDA boxed warning.
Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload,Avoid rapid administration to prevent hypervolemia and electrolyte disturbances,Contains potassium; use cautiously in patients with hyperkalemia or conditions predisposing to potassium retention,Contains calcium; do not administer simultaneously with blood products through the same IV line due to risk of precipitation
Hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome) in patients with penicillin allergy,Clostridioides difficile-associated diarrhea,Hepatic toxicity (elevated liver enzymes, hepatitis, cholestatic jaundice) more common in elderly and with prolonged use,Renal impairment requires dose adjustment,Risk of superinfection with prolonged therapy,Skin rash can occur in patients with mononucleosis
Hypersensitivity to any component of the solution,Hyperkalemia,Hypercalcemia,Severe metabolic alkalosis,Patients with significant fluid overload or pulmonary edema,Concomitant administration with blood products via same IV line
History of anaphylactic reaction to penicillins or cephalosporins,Previous cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate,Concurrent use with disulfiram or probenecid (relative)
No specific food interactions. However, consider overall fluid and electrolyte intake from diet, especially sodium and potassium, to avoid imbalances.
May be taken with or without food; food enhances absorption; avoid ingestion with high-dose clavulanate? (no significant interaction); no specific food restrictions; milk-containing products do not interact significantly.
Physiosol in plastic container is a sterile, non-pyrogenic isotonic solution of electrolytes and water. It contains no known teratogenic agents. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this solution. Therefore, it should be used during pregnancy only if clearly needed. No specific fetal risks have been identified for any trimester when used as directed.
Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Use during first trimester is considered safe if clinically indicated. During second and third trimesters, no known fetal risks. However, avoid use near term due to potential for neonatal kernicterus (theoretical risk from high doses, but not confirmed).
Safety in breastfeeding has not been established. Since Physiosol is a balanced electrolyte solution, it is unlikely to pose significant risk to the nursing infant. However, caution is advised. The milk-to-plasma (M/P) ratio is not available.
Amoxicillin and clavulanate are excreted into breast milk in low concentrations. M/P ratio not established. Considered compatible with breastfeeding by AAP; risk of infant sensitization, diarrhea, or thrush. Use with caution in infants with history of penicillin allergy.
No specific dosing adjustments are required for pregnancy based on pharmacokinetic changes. However, pregnant patients may have increased plasma volume, and fluid and electrolyte requirements should be individualized. Caution is advised in preeclampsia or conditions with fluid overload.
Pharmacokinetic changes in pregnancy (increased renal clearance, expanded plasma volume) may require dose adjustments: total daily dose typically remains same but dosing interval may need to be shortened (e.g., every 6-8 hours instead of every 12 hours) for severe infections; monitor clinical response. No standard recommendation for routine adjustment; base on severity and renal function.
Physiosol in plastic container is a balanced electrolyte solution for intravenous administration, primarily used for replacement of extracellular fluid losses. Monitor for signs of fluid overload, especially in patients with heart failure or renal impairment. The plastic container may leach phthalates; use with caution in neonates and pregnant women. Do not administer if solution is discolored or contains particulate matter.
Use weight-based dosing for pediatric patients; reconstitute oral suspension with appropriate amount of water; administer at start of meal to reduce GI upset; check renal function before dosing; avoid in patients with mononucleosis due to risk of maculopapular rash; higher doses of clavulanate may cause diarrhea; intravenous infusion over 30-40 minutes; consider penicillin allergy cross-reactivity; not effective against MRSA; requires dose adjustment in Cr Cl <30 m L/min.
This solution is given intravenously to replace fluids and electrolytes.,Report any signs of allergic reaction, such as rash, itching, or difficulty breathing.,Notify your healthcare provider if you experience swelling, shortness of breath, or rapid weight gain.,Do not stop the infusion without consulting your doctor.
Take this medication exactly as prescribed, usually every 12 hours.,Take with food to reduce stomach upset and improve absorption.,Complete the full course even if you feel better.,Shake the oral suspension well before each use.,Store oral suspension in refrigerator, discard after 10 days.,Report severe diarrhea, rash, or signs of allergy immediately.,May cause diarrhea; do not treat without consulting doctor.,Inform your doctor if you are pregnant, breastfeeding, or have liver disease.
No interactions on record
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHYSIOSOL IN PLASTIC CONTAINER vs AMOXICILLIN AND CLAVULANATE POTASSIUM, answered by our medical review team.
PHYSIOSOL IN PLASTIC CONTAINER is a Irrigation Solution that works by PHYSIOSOL is a sterile, non-pyrogenic isotonic solution of electrolytes (sodium, potassium, calcium, magnesium, chloride, acetate, and gluconate) in water for injection. It serves as a source of water and electrolytes to expand extracellular fluid volume and maintain osmotic balance. The acetate and gluconate ions are metabolized to bicarbonate, providing an alkalinizing effect.. AMOXICILLIN AND CLAVULANATE POTASSIUM is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHYSIOSOL IN PLASTIC CONTAINER and AMOXICILLIN AND CLAVULANATE POTASSIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHYSIOSOL IN PLASTIC CONTAINER is: Intravenous infusion; dose based on fluid and electrolyte requirements; typical adult dose: 500-1000 m L/h as needed to maintain hydration and electrolyte balance.. The standard adult dose of AMOXICILLIN AND CLAVULANATE POTASSIUM is: 500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHYSIOSOL IN PLASTIC CONTAINER and AMOXICILLIN AND CLAVULANATE POTASSIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHYSIOSOL IN PLASTIC CONTAINER is classified as Category C. Physiosol in plastic container is a sterile, non-pyrogenic isotonic solution of electrolytes and water. It contains no known teratogenic agents. There are no adequate and well-cont. AMOXICILLIN AND CLAVULANATE POTASSIUM is classified as Category A/B. Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.